CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 136 filers reported holding CYTOMX THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 12.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $30,000 | -18.9% | 5,922 | 0.0% | 0.00% | – |
| Q2 2021 | $37,000 | -19.6% | 5,922 | 0.0% | 0.00% | – |
| Q1 2021 | $46,000 | +17.9% | 5,922 | 0.0% | 0.00% | – |
| Q4 2020 | $39,000 | 0.0% | 5,922 | 0.0% | 0.00% | – |
| Q3 2020 | $39,000 | -20.4% | 5,922 | 0.0% | 0.00% | – |
| Q2 2020 | $49,000 | +157.9% | 5,922 | +141.4% | 0.00% | – |
| Q1 2020 | $19,000 | -5.0% | 2,453 | 0.0% | 0.00% | – |
| Q4 2019 | $20,000 | +11.1% | 2,453 | 0.0% | 0.00% | – |
| Q3 2019 | $18,000 | -35.7% | 2,453 | 0.0% | 0.00% | – |
| Q2 2019 | $28,000 | +7.7% | 2,453 | 0.0% | 0.00% | – |
| Q1 2019 | $26,000 | -29.7% | 2,453 | 0.0% | 0.00% | – |
| Q4 2018 | $37,000 | -17.8% | 2,453 | 0.0% | 0.00% | – |
| Q3 2018 | $45,000 | -19.6% | 2,453 | 0.0% | 0.00% | – |
| Q2 2018 | $56,000 | -40.4% | 2,453 | -25.5% | 0.00% | -100.0% |
| Q1 2018 | $94,000 | +36.2% | 3,291 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $69,000 | – | 3,291 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 476,110 | $3,956,000 | 2.65% |
| MPM BioImpact LLC | 855,437 | $7,109,000 | 2.52% |
| Exane Asset Management | 87,876 | $730,250,000 | 0.90% |
| Congress Park Capital LLC | 94,661 | $787,000 | 0.58% |
| Perceptive Advisors | 3,253,923 | $27,040,000 | 0.54% |
| BVF INC/IL | 766,148 | $6,367,000 | 0.48% |
| RTW INVESTMENTS, LP | 1,039,593 | $8,639,000 | 0.33% |
| EcoR1 Capital, LLC | 410,000 | $3,407,000 | 0.31% |
| DAFNA Capital Management LLC | 100,000 | $831,000 | 0.28% |
| HARBOURVEST PARTNERS LLC | 79,193 | $658,000 | 0.27% |